Trial
NCT02785900
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Seagen Inc.
Collaborators
—
Condition
Acute Myeloid Leukemia
Intervention
33A
Why stopped
Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm versus the control arm
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-12-12